New Companies Formed by the St. Louis Regional i6 ... - BioGenerator

guiltlesscyanBiotechnology

Dec 3, 2012 (4 years and 8 months ago)

234 views

BioGenerator

www.BioGenerator.org

4041 Forest Park Avenue

St. Louis, Missouri, 63108

(314).615.6355


New Companies Formed by the St. Louis Regional i6 Project


X
-
tend Energy
, LLC

produces high
-
performance materials for
lithium
-
ion
batteries
. By combining a groundbreaking process with innovative materials,
X
-
tend Energy addresses
the
critical
challenges limiting

electric vehicle

adoption.
X
-
tend
Energy’s revolutionary

new products
,

based on intellectual
property developed by Dr. Richard Axelbaum

at
Washington University
,

are
expected to change the electric vehicle marketplace.




Confluence
Discovery Technologies
, Inc

is a contract research organization
(CRO) providing
specialty services t
o the pharmaceutical
industry
.
Confluence’s
KINect Technology

platform is an enabling

technology for targeting
the Kinase protein family.

The company offers
world cla
ss scientific problem
solving

in the areas of medicinal chemistry, biochemistry, assay development,
biomarker identification and development
,

and target validation.


Apertus Pharmaceuticals
, LLC

is a
C
ontr
act M
anufacturing
O
rganization

(CMO) producing

Active Pharmaceutical Ingredients

(API)
for use in

the
pharmaceutical industry
.
Target customers
are organizations that outsource
manu
facturing

of APIs.

The company has four initial products

represent
ing

a
rapidly
growing subset of the
market.

Apertus Pharma
ceuticals

also

offers
formulation development and analytical services

for API production
.



Euclises Pharmaceuticals
, Inc

is developing
novel pain
and cancer
medications

that offer superior safety margins compared to existing drugs.
Th
e company is
based on new inventions from

Dr. John Talley
, the most
accomplished medicinal
chemist in the world
. Dr. Talley previously
invented
Celebrex and seven other

approved drugs
.

New compounds
from
Euclises
will offer both
improved efficacy
and
safety

relative to existing therapies.



RadTargX Therapeutics
, Inc

is developing
novel approaches to cancer
treatment

using monoclonal antibodies that target changes to cancer cell
s
following radiation therapy.
The
therapies are designed to

enhance the
efficacy obtained through radiation therapy

and are highly selective for
cancerous tissue.

RadTargX is based on intellectual property licensed from
Washington University

and developed

by Dr. Dennis Hallahan.



Array Bridge
, Inc

is a
research tools and services company

that offers
innovative technologies to drug development companies
that are
producing
biotherapeutics
.
Key products include
detection systems

used to
quantify
impurities

and determine conformational state for protein
-
based drugs
, critical
data for biotherapeutic and
biosimilar

production
.

The company additionally
offers contract services

for imp
urity and conformational analysi
s.


ARTA Bioscience
, Inc

is developing new therapeutics for
prostate cancer
and inflammatory diseases
.

Current treatments for prostate cancer are
insufficient
;

the disease is

the
second leading cause of cancer deaths

among American men
. Compared to traditional
therapies
,
ARTA
’s

technology
involves

an entirely diff
erent approach to combating
disease.

The

technology

was developed by

Dr. Marc Diamond
of

Washington University
.


Apse
,

LLC
is a biotechnology company seeking to commercialize a portfolio of
novel nanocontainers

for use in
developing and manufacturing
protein
-
based drugs
.
By simplifying the production process, Apse’s nan
ocontainers will
lower the
costs

associated with this

important

class of

medicines
.
Nanocontainers

have application at all stages of drug development, from early
production of research materials to manufacturing of biological medicines.